RemeGen Co., Ltd.

SEHK:9995 Stock Report

Market Cap: HK$12.9b

RemeGen Future Growth

Future criteria checks 5/6

RemeGen is forecast to grow earnings and revenue by 51.2% and 23.1% per annum respectively. EPS is expected to grow by 55.3% per annum. Return on equity is forecast to be 9.9% in 3 years.

Key information

51.2%

Earnings growth rate

55.3%

EPS growth rate

Biotechs earnings growth38.6%
Revenue growth rate23.1%
Future return on equity9.9%
Analyst coverage

Good

Last updated20 Jan 2025

Recent future growth updates

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 20
RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Recent updates

The Market Doesn't Like What It Sees From RemeGen Co., Ltd.'s (HKG:9995) Revenues Yet As Shares Tumble 30%

Jan 12
The Market Doesn't Like What It Sees From RemeGen Co., Ltd.'s (HKG:9995) Revenues Yet As Shares Tumble 30%

There's No Escaping RemeGen Co., Ltd.'s (HKG:9995) Muted Revenues Despite A 25% Share Price Rise

Nov 27
There's No Escaping RemeGen Co., Ltd.'s (HKG:9995) Muted Revenues Despite A 25% Share Price Rise

Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

Sep 28
Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 20
RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Jul 22
Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21
Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24
Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18
RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29
Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16
RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Aug 03
Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Jun 22
Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

May 10
RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Mar 09
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

May 04
RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08
RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23
RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21
We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

SEHK:9995 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20274,0985712801,5663
12/31/20263,254-411-324-17215
12/31/20252,441-932-886-71215
12/31/20241,776-1,603-1,352-1,0155
9/30/20241,522-1,552-1,544-1,223N/A
6/30/20241,402-1,588-2,178-1,615N/A
3/31/20241,245-1,536-2,354-1,579N/A
12/31/20231,083-1,511-2,356-1,503N/A
9/30/2023972-1,341-2,150-1,295N/A
6/30/2023844-1,213-2,071-1,269N/A
3/31/2023790-1,036-2,007-1,260N/A
12/31/2022772-999-2,013-1,260N/A
9/30/20221,879276-894-97N/A
6/30/20221,745231-60990N/A
3/31/20221,570174-474185N/A
12/31/20211,424276-354264N/A
9/30/2021115-912-1,483-921N/A
6/30/202129-892-1,493-927N/A
3/31/20214-783-1,326-814N/A
12/31/2020N/A-698-1,141-660N/A
9/30/2020N/A-588-906-543N/A
6/30/2020N/A-478-671-427N/A
3/31/2020N/A-442-487-343N/A
12/31/2019N/A-430-348-283N/A
12/31/201811-270-212-128N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9995 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 9995 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 9995 is expected to become profitable in the next 3 years.

Revenue vs Market: 9995's revenue (23.1% per year) is forecast to grow faster than the Hong Kong market (7.6% per year).

High Growth Revenue: 9995's revenue (23.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9995's Return on Equity is forecast to be low in 3 years time (9.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 23:41
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RemeGen Co., Ltd. is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Shun Kei LawCCB International Securities Limited